logo
Plus   Neg
Share
Email

Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan

Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Steglatro (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 or SGLT2 inhibitor, and the fixed-dose combination Steglujan (ertugliflozin and sitagliptin) tablets.

Steglatro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.

Steglatro and Steglujan are not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Steglujan has not been studied in patients with a history of pancreatitis and it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Steglujan.

Steglatro and Steglujan are contraindicated in patients with severe renal impairment, end-stage renal disease or on dialysis, or with a history of a serious hypersensitivity reaction to ertugliflozin. Steglujan is also contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin (such as anaphylaxis or angioedema).

These FDA approvals are supported by seven Phase 3 studies of approximately 4,800 patients. Steglatro was studied as monotherapy and in combination with metformin and/or sitagliptin, as well as with insulin and a sulfonylurea, in adults with type 2 diabetes and moderate renal impairment.

Diabetes is a chronic, progressive disease affecting approximately 30 million Americans. About one-third of adults with type 2 diabetes in the U.S. are not at their A1C goal.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Nike Inc. (NKE), the world's largest athletic shoes and apparel maker, Tuesday reported a first-quarter profit that increased from a year ago and trumped Wall Street estimates, driven largely by more-than-expected revenues and strong margins. Beaverton, Oregon-based Nike's first-quarter profit rose... German auto giant BMW (BMW.L, BAMXF.PK, BAMXY.PK) Tuesday lowered its earnings and revenue guidance for the full year 2018, hurt largely by emissions-related costs, product recalls and ongoing global trade war. Automotive segment revenues are now expected to be slightly lower than the previous year.... Walt Disney World is introducing a new ticket pricing system in order to better distribute attendance at its theme parks throughout the year. The company plans to begin pricing tickets for its theme parks based on dates so as to reflect the expected demand on specific days. Disney said Monday that beginning October 16, guests will be able to access its new online vacation-booking portal.
Follow RTT